The hyperlipidemia: Attitudes and beliefs in treatment (habit) survey for patients: Results of a validation study

Journal of Cardiovascular Nursing

Volumn 20, Issue 1, 2005, Pages 35-42

  Foley, Kathleen A ^a   Vasey, Joseph ^a   Berra, Kathleen ^a   Alexander, Charles M ^a   Markson, Leona E ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Health attitudes; Hyperlipidemia; Pharmacological therapy; Treatment effectiveness

Indexed keywords

ANTILIPEMIC AGENT;

ARTICLE; ATTITUDE TO HEALTH; FACTORIAL ANALYSIS; FEMALE; HUMAN; HUMAN RELATION; HYPERLIPIDEMIA; INTERPERSONAL COMMUNICATION; LIFESTYLE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; PREDICTION AND FORECASTING; PSYCHOLOGICAL ASPECT; PSYCHOMETRY; QUESTIONNAIRE; STANDARD; STATISTICS; TREATMENT OUTCOME; VALIDATION STUDY;

ANTILIPEMIC AGENTS; COMMUNICATION; FACTOR ANALYSIS, STATISTICAL; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; HYPERLIPIDEMIAS; LIFE STYLE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION; PREDICTIVE VALUE OF TESTS; PROFESSIONAL-PATIENT RELATIONS; PSYCHOMETRICS; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 14744275711     PISSN: 08894655     EISSN: 15505049     Source Type: Journal    
DOI: 10.1097/00005082-200501000-00008     Document Type: Article

References (25)

1. Pearson T, Peters T. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol. 1997;80(8B):45H-52H.
2. Marcelino J, Feingold K. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 1996;100(6):605-610.
3. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461.
4. Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart. 2002;88:203-206.
5. Vermeire E, Hearnshaw H, Van Royen P, Denekens J. Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther. 2001;26: 331-342.
6. Ajzen I, Fishbein M. Understanding Attitudes and Predicting Social Behavior. Englewood Cliffs, NJ: Prentice-Hall; 1980.
7. Weir M, Maiback E, Bakris G, et al. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000;160:481-490.
8. Insull W. The problem of compliance to cholesterol altering therapy. J Intern Med. 1997;241:317-325.
9. Svensson S, Kjellgren KI, Ahlmer J, Saljo R. Reasons for adherence with antihypertensive medication. Int J Cardiol. 2000;76:157-163.
10. LaRosa JH, LaRosa JC. Enhancing drug compliance in lipid-lowering treatment. Arch Fam Med. 2000;9:1169-1175.
11. Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications for primary care. Am J Manag Care. 1999;5(4):437-444.
12. Kiortsis DN, Giral P, Bruckert E, Turpin G. Factors associated with low compliance with lipid-lowering drugs in hyperlipidemic patients. J Clin Pharm Ther. 2000;25:445-451.
13. Parker RM, Jacobson TA. The role of health literacy in narrowing the treatment gap for hypercholesterolemia. Am J Manag Care. 2000;6:1340-1342.
14. Troein M, Rastam L, Selander S, Widlund M, Uden G. Understanding the unperceivable: ideas about cholesterol expressed by middle-aged men with recently discovered hypercholesterolaemia. Fam Pract. 1997;14(5):376-381.
15. Rybacki JJ. Improving cardiovascular health in postmenopausal women by addressing medication adherence issues. J Am Pharm Assoc. 2002;42:63-73.
16. Anderson RM, Donnelly MB, Dedrick RF. Measuring the attitudes of patients towards diabetes and its treatment. Patient Educ Couns. 1990;16:231-245.
17. Bairey Merz CN, Buse JB, Tuncer C, Twillman GB. Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol. 2002;40(10):1877-1881.
18. Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining national cholesterol education program low-density lipoprotein cholesterol goals with five statins. Am J Med. 2001;111:185-191.
19. Brown AS, Bakker-Arkema RG, Yellen L, et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program—recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Card. 1998;32:665-672.
20. Foley KA, Simpson RJ Jr, Crouse JR III, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol. 2003;92:79-81.
21. Thompson B, Daniel L. Factor analytic evidence for the construct validity of scores: a historical overview and some guidelines. Educ Psychol Meas. 1996;56(2):197-208.
22. Ockene IS, Hayman LL, Pasternak RC, Schron E, Dunbar-Jacob J. Task Force #4—Adherence issues and behavior changes: achieving a long-term solution. J Am Coll Cardiol. 2002;40(4):630-640.
23. Foley KA, Vasey J, Alexander CM, Markson LE. The development and validation of the Hyperlipidemia: Attitudes and Beliefs in Treatment (HABIT) survey for physicians. J Gen Intern Med. 2003;18:984-990.
24. Anderson R, Donnelly M, Gressard C, Dedrick R. Development of diabetes attitude scale for health-care professionals. Diabetes Care. 1989;12(2):120-127.
25. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360:7-22.